AstraZeneca PLC ADR underperforms Thursday when compared to competitors despite daily gains
This was the ADR's second consecutive day of gains.
Guggenheim Sticks to Their Buy Rating for AstraZeneca (AZN)
In a report released yesterday, Seamus Fernandez from Guggenheim reiterated a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
UBS Sticks to Their Hold Rating for AstraZeneca (AZN)
UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...
wahanariau2d
AstraZeneca achieves top rankings as Best Place to Work across North Africa and Levant in 2024
DUBAI, UAE - - 28 January 2025 - AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been ...
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
News Medical3d
Blood test for ctDNA identifies patients who benefit from celecoxib after surgery
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...
News Medical5d
AstraZeneca receives positive NICE recommendations for lung cancer treatment
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...